Biotech Investment Analyst — Drug Asset & Company Assessment

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We’re seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.

Responsibilities

• Create and critique rubrics that analyze commercial drugs and drug-development programs
• Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
• Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
• Apply your assessment across the pilot’s set of companies (~5–10)

Requirements

• US-based biotech / healthcare investment analyst with a specialist-fund background
• Familiarity with biotech/pharma development programs
• Able to assess a drug asset and the company behind it end-to-end
• 5+ years evaluating biotech/pharma companies or assets

Engagement Details

• Duration: Approximately 10–20 hours over a 1–2 week pilot
• Remote — US-based

Why Participate

• Help improve expert AI evaluation of drugs and drug-development programs
• Recurring engagement for strong contributors

Compensation

• Pay: $120 – $200/hour
• Type: Part-time contract
• Location: Remote — US-based or deep US-market experience